MA50116A1 - Agent d'absorption transdermique comprenant du donépézil pour le traitement de la démence - Google Patents

Agent d'absorption transdermique comprenant du donépézil pour le traitement de la démence

Info

Publication number
MA50116A1
MA50116A1 MA50116A MA50116A MA50116A1 MA 50116 A1 MA50116 A1 MA 50116A1 MA 50116 A MA50116 A MA 50116A MA 50116 A MA50116 A MA 50116A MA 50116 A1 MA50116 A1 MA 50116A1
Authority
MA
Morocco
Prior art keywords
treatment
dementia
transdermal absorption
absorption agent
donepezil
Prior art date
Application number
MA50116A
Other languages
English (en)
Other versions
MA50116B2 (fr
Inventor
Sun-Woo Jang
Chang-Yell Shin
Jeong-Soo Kim
Hae-Sun Kim
Kwang-Ho Cha
Hyun-Jung Kim
Masaoki Goto
Original Assignee
Dong A St Co Ltd
Km Transderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A St Co Ltd, Km Transderm Ltd filed Critical Dong A St Co Ltd
Publication of MA50116A1 publication Critical patent/MA50116A1/fr
Publication of MA50116B2 publication Critical patent/MA50116B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
    • A61F2013/0296—Apparatus or processes for manufacturing adhesive dressings or bandages for making transdermal patches (chemical processes excluded)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D7/00—Producing flat articles, e.g. films or sheets
    • B29D7/01—Films or sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2071/00—Use of polyethers, e.g. PEEK, i.e. polyether-etherketone or PEK, i.e. polyetherketone or derivatives thereof, as moulding material
    • B29K2071/02—Polyalkylene oxides, e.g. PEO, i.e. polyethylene oxide, or derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un agent d'absorption transdermique comprenant du donépézil pour le traitement de la démence et, plus particulièrement, un agent d'absorption transdermique pour le traitement de la démence, l'agent comprenant : (a) le donépézil en tant que principe actif ; (b) le monocaprylate de propylène glycol en tant que solubilisant ; et (c) un copolymère séquencé de styrène-isoprène-styrène en tant que matériau de base adhésif. L'agent d'absorption transdermique pour le traitement de la démence selon la présente invention entraîne une faible irritation cutanée et simultanément présente une excellente perméabilité cutanée.
MA50116A 2017-12-27 2018-11-07 Agent d'absorption transdermique comprenant du donépézil pour le traitement de la démence MA50116B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170180647A KR102024996B1 (ko) 2017-12-27 2017-12-27 도네페질을 함유하는 치매 치료용 경피흡수제제
PCT/KR2018/013439 WO2019132229A1 (fr) 2017-12-27 2018-11-07 Agent d'absorption transdermique comprenant du donépézil pour le traitement de la démence

Publications (2)

Publication Number Publication Date
MA50116A1 true MA50116A1 (fr) 2021-09-30
MA50116B2 MA50116B2 (fr) 2023-03-31

Family

ID=67067659

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50116A MA50116B2 (fr) 2017-12-27 2018-11-07 Agent d'absorption transdermique comprenant du donépézil pour le traitement de la démence

Country Status (13)

Country Link
US (1) US11992562B2 (fr)
EP (1) EP3733168A4 (fr)
JP (1) JP7170728B2 (fr)
KR (1) KR102024996B1 (fr)
CN (1) CN111542311B (fr)
AU (1) AU2018395643B2 (fr)
BR (1) BR112020013187A2 (fr)
CA (1) CA3087156C (fr)
CL (1) CL2020001738A1 (fr)
MA (1) MA50116B2 (fr)
MX (1) MX2020006645A (fr)
WO (1) WO2019132229A1 (fr)
ZA (1) ZA202004530B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102218593B1 (ko) * 2020-05-13 2021-02-22 동아에스티 주식회사 안정성이 향상된 도네페질 함유 경피 흡수제제
KR102489860B1 (ko) * 2021-09-02 2023-01-19 동아에스티 주식회사 메만틴 에난트산염을 포함하는 치매 치료용 경피흡수 제제

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3987655B2 (ja) 1998-03-03 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬を含有した経皮適用製剤又は坐剤
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
JP4394443B2 (ja) * 2001-10-17 2010-01-06 久光製薬株式会社 経皮吸収型製剤
DE10159120B4 (de) * 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
US7744918B2 (en) 2004-11-22 2010-06-29 Hisamitsu Pharmaceutical Co., Inc. Drug-containing patch
US20080131491A1 (en) * 2006-12-01 2008-06-05 Akinori Hanatani Percutaneously absorbable preparation
KR101454362B1 (ko) * 2008-03-24 2014-10-23 아이큐어 주식회사 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
EP2328582A4 (fr) 2008-09-30 2012-02-22 Teikoku Pharma Usa Inc Compositions de donépézil à administration transdermique étendue et leurs procédés d'utilisation
KR101325104B1 (ko) 2009-09-16 2013-11-07 주식회사 삼양바이오팜 경피 투여 제형 및 그 제조 방법
BR112012011334A2 (pt) * 2009-10-21 2020-08-25 Teikoku Seiyaku Co., Ltd. formulação transdermicamente absorvível contendo donepezil
KR101292768B1 (ko) * 2010-04-23 2013-08-05 아이큐어 주식회사 경피 흡수 제제
US20130053358A1 (en) 2010-04-28 2013-02-28 Hisamitsu Pharmaceutical Co., Inc. Transdermally absorbable donepezil-containing preparation
JPWO2012029097A1 (ja) 2010-09-03 2013-10-28 株式会社 ケイ・エム トランスダーム 経皮吸収製剤
WO2013035850A1 (fr) * 2011-09-08 2013-03-14 株式会社 ケイ・エム トランスダーム Préparation transdermique
KR101239150B1 (ko) 2012-02-28 2013-03-06 에스케이케미칼주식회사 도네페질-함유 경피흡수제제 및 그의 제조방법
KR101485822B1 (ko) 2014-01-22 2015-01-23 주식회사 대웅제약 도네페질 또는 그의 염을 함유하는 경피흡수제제
KR20160120778A (ko) * 2014-02-20 2016-10-18 날 파마슈티칼 그룹 리미티드 도네페질을 함유하는 경피흡수제제
HUE048569T2 (hu) * 2014-12-18 2020-07-28 Icure Pharm Inc Hatóanyagként donepezilt tartalmazó transzdermális készítmény
TW201940199A (zh) * 2018-01-22 2019-10-16 日商鐘化股份有限公司 皮膚貼附用黏著片材

Also Published As

Publication number Publication date
WO2019132229A1 (fr) 2019-07-04
US11992562B2 (en) 2024-05-28
AU2018395643A1 (en) 2020-07-02
ZA202004530B (en) 2021-09-29
AU2018395643B2 (en) 2023-02-16
BR112020013187A2 (pt) 2020-12-01
CN111542311A (zh) 2020-08-14
CA3087156C (fr) 2023-08-01
CA3087156A1 (fr) 2019-07-04
JP7170728B2 (ja) 2022-11-14
KR20190078893A (ko) 2019-07-05
CN111542311B (zh) 2023-07-14
US20210059956A1 (en) 2021-03-04
MA50116B2 (fr) 2023-03-31
RU2020123498A (ru) 2022-01-27
KR102024996B1 (ko) 2019-09-25
RU2020123498A3 (fr) 2022-01-27
CL2020001738A1 (es) 2020-11-06
EP3733168A1 (fr) 2020-11-04
MX2020006645A (es) 2020-11-06
EP3733168A4 (fr) 2021-09-08
JP2021508713A (ja) 2021-03-11

Similar Documents

Publication Publication Date Title
CO2022003782A2 (es) Inhibidores de kras g12d
MX2020009390A (es) Suministro transdermico y/o dermico de agentes activos lipofilicos.
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CL2020001271A1 (es) Inhibidores de kras g12c
SG11201810270SA (en) Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
CL2020002252A1 (es) Formulación oftálmica.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
EA201891225A1 (ru) Пленкообразующий спрей для местного применения
MA47736B1 (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
BR112022002289A2 (pt) Composições de curativo líquido e seus usos veterinários
MY193312A (en) Topical formulation for promoting wound healing
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX2022008479A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
BR112022008365A2 (pt) Inibidores de cd73
CO2020015377A2 (es) Moduladores de la expresión de apol1
MA50116A1 (fr) Agent d'absorption transdermique comprenant du donépézil pour le traitement de la démence
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
MA36538B1 (fr) Utilisation de composition a base d'extraits de microalgues marines pour le traitement d'acne
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
PE20200749A1 (es) Moduladores de la expresion de enac
FR3074421B1 (fr) Extrait d'helichrysum gymnocephalum pour le traitement et/ou la prevention des dermatoses inflammatoires
CY1125444T1 (el) Συνθεσεις εναντι μολυνσεων καντιντιασης